BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7578977)

  • 1. Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130.
    de Hon FD; ten Boekel E; Herrman J; Clement C; Ehlers M; Taga T; Yasukawa K; Ohsugi Y; Kishimoto T; Rose-John S
    Cytokine; 1995 Jul; 7(5):398-407. PubMed ID: 7578977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.
    de Hon FD; Ehlers M; Rose-John S; Ebeling SB; Bos HK; Aarden LA; Brakenhoff JP
    J Exp Med; 1994 Dec; 180(6):2395-400. PubMed ID: 7964514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of residues in the putative 5th helical region of human interleukin-6, important for activation of the IL-6 signal transducer, gp130.
    Brakenhoff JP; Bos HK; Grötzinger J; Rose-John S; Aarden LA
    FEBS Lett; 1996 Oct; 395(2-3):235-40. PubMed ID: 8898103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells.
    Ehlers M; de Hon FD; Bos HK; Horsten U; Kurapkat G; van De Leur HS; Grötzinger J; Wollmer A; Brakenhoff JP; Rose-John S
    J Biol Chem; 1995 Apr; 270(14):8158-63. PubMed ID: 7713920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
    Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
    J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
    Liautard J; Sun RX; Cotte N; Gaillard JP; Mani JC; Klein B; Brochier J
    Cytokine; 1997 Apr; 9(4):233-41. PubMed ID: 9112331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.
    Zhang XG; Gu JJ; Lu ZY; Yasukawa K; Yancopoulos GD; Turner K; Shoyab M; Taga T; Kishimoto T; Bataille R
    J Exp Med; 1994 Apr; 179(4):1337-42. PubMed ID: 8145045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation.
    Ehlers M; Grötzinger J; Fischer M; Bos HK; Brakenhoff JP; Rose-John S
    J Interferon Cytokine Res; 1996 Aug; 16(8):569-76. PubMed ID: 8877726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of amino acid residues of gp130 signal transducer and gp80 alpha receptor subunit that are involved in ligand binding and signaling by human herpesvirus 8-encoded interleukin-6.
    Li H; Nicholas J
    J Virol; 2002 Jun; 76(11):5627-36. PubMed ID: 11991991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp.
    Peppard JV; Loo P; Sills MA; Munster D; Pomponi SA; Wright AE
    J Biol Chem; 1996 Mar; 271(13):7281-4. PubMed ID: 8631742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity.
    Sun RX; Gennaro C; Rocco S; Gu ZJ; Klein B
    Eur Cytokine Netw; 1997 Mar; 8(1):51-6. PubMed ID: 9110148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation.
    Anhuf D; Weissenbach M; Schmitz J; Sobota R; Hermanns HM; Radtke S; Linnemann S; Behrmann I; Heinrich PC; Schaper F
    J Immunol; 2000 Sep; 165(5):2535-43. PubMed ID: 10946280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.
    Nishimoto N; Ogata A; Shima Y; Tani Y; Ogawa H; Nakagawa M; Sugiyama H; Yoshizaki K; Kishimoto T
    J Exp Med; 1994 Apr; 179(4):1343-7. PubMed ID: 8145046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.
    Savino R; Lahm A; Salvati AL; Ciapponi L; Sporeno E; Altamura S; Paonessa G; Toniatti C; Ciliberto G
    EMBO J; 1994 Mar; 13(6):1357-67. PubMed ID: 7511100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional expression of soluble human interleukin-11 (IL-11) receptor alpha and stoichiometry of in vitro IL-11 receptor complexes with gp130.
    Neddermann P; Graziani R; Ciliberto G; Paonessa G
    J Biol Chem; 1996 Nov; 271(48):30986-91. PubMed ID: 8940087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
    Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells.
    Sporeno E; Savino R; Ciapponi L; Paonessa G; Cabibbo A; Lahm A; Pulkki K; Sun RX; Toniatti C; Klein B; Ciliberto G
    Blood; 1996 Jun; 87(11):4510-9. PubMed ID: 8639818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface.
    Salvati AL; Lahm A; Paonessa G; Ciliberto G; Toniatti C
    J Biol Chem; 1995 May; 270(20):12242-9. PubMed ID: 7744875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130.
    Kurth I; Horsten U; Pflanz S; Timmermann A; Küster A; Dahmen H; Tacken I; Heinrich PC; Müller-Newen G
    J Immunol; 2000 Jan; 164(1):273-82. PubMed ID: 10605021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a human interleukin-6 receptor antagonist.
    Brakenhoff JP; de Hon FD; Fontaine V; ten Boekel E; Schooltink H; Rose-John S; Heinrich PC; Content J; Aarden LA
    J Biol Chem; 1994 Jan; 269(1):86-93. PubMed ID: 8276883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.